OX40 is a potent immune-stimulating target in late-stage cancer patients

Cancer Research

Volumn 73, Issue 24, 2013, Pages 7189-7198

  Curti, Brendan D ^a   Kovacsovics Bankowski, Magdalena ^a   Morris, Nicholas ^a   Walker, Edwin ^a   Chisholm, Lana ^a   Floyd, Kevin ^a   Walker, Joshua ^b   Gonzalez, Iliana ^a   Meeuwsen, Tanisha ^a   Fox, Bernard A ^a   Moudgil, Tarsem ^a   Miller, William ^a   Haley, Daniel ^a   Coffey, Todd ^a   Fisher, Brenda ^a   Delanty Miller, Laurie ^a   Rymarchyk, Nicole ^a   Kelly, Tracy ^a   Crocenzi, Todd ^a   Bernstein, Eric ^a   Sanborn, Rachel ^a   Urba, Walter J ^a   Weinberg, Andrew D ^a   more..

^a EARLE A CHILES RESEARCH INSTITUTE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CD4 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 9B12; PROTEIN OX40; RECEPTOR; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANEMIA; ARTHRALGIA; ARTICLE; B LYMPHOCYTE; CANCER IMMUNIZATION; CANCER REGRESSION; CANCER STAGING; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG POTENCY; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; FEVER; HELPER CELL; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOPENIA; MELANOMA; METASTASIS; MYALGIA; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; REGULATORY T LYMPHOCYTE; SKIN DISEASE; SPLENOMEGALY; T LYMPHOCYTE; TOXICITY TESTING; TUMOR ASSOCIATED LEUKOCYTE; UPREGULATION; VALIDATION STUDY; VOMITING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HUMANS; LYMPHOCYTE ACTIVATION; MICE; NEOPLASMS; RECEPTORS, OX40; T-LYMPHOCYTES, REGULATORY;

EID: 84891275907     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-4174     Document Type: Article

References (37)

1. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007;7:95-106.
2. Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: The first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 2008;26:5275-83.
3. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 2009;206:1717-25.
4. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010;107:4275-80.
5. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX- 1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28:3167-75.
6. Weber J. Immune checkpoint proteins: A new therapeutic paradigm for cancer-preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol 2010;37:430-9.
7. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
8. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-65.
9. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
10. Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008;14:3044-51.
11. Sznol M, Hodi FS, Margolin K, McDermott DF, Ernstoff MS, Kirkwood JM, et al. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). J Clin Oncol 26:15s, 2008 (suppl; abstr 3007)
12. Kjaergaard J, Tanaka J, Kim JA, Rothchild K, Weinberg A, Shu S. Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res 2000;60:5514-21.
13. Weinberg AD, Rivera MM, Prell R, Morris A, Ramstad T, Vetto JT, et al. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol 2000;164:2160-9.
14. Gough MJ, Ruby CE, Redmond WL, Dhungel B, Brown A, Weinberg AD. OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. Cancer Res 2008; 68:5206-15.
15. Piconese S, Valzasina B, Colombo MP. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J ExpMed 2008;205:825-39.
16. Paterson DJ, Jefferies WA, Green JR, Brandon MR, Corthesy P, Puklavec M, et al. Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts. Mol Immunol 1987;24:1281-90.
17. Mallett S, Fossum S, Barclay AN. Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes - a molecule related to nerve growth factor receptor. EMBO J 1990;9:1063-8.
18. Calderhead DM, Buhlmann JE, van den Eertwegh AJ, Claassen E, Noelle RJ, Fell HP. Cloning of mouse Ox40: A T cell activation marker that may mediate T-B cell interactions. J Immunol 1993;151: 5261-71.
19. Gramaglia I, Weinberg AD, Lemon M, Croft M. Ox-40 ligand: A potent costimulatory molecule for sustaining primary CD4 T cell responses. J Immunol 1998;161:6510-7.
20. Gramaglia I,Jember A, Pippig SD, Weinberg AD, Killeen N, Croft M. The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J Immunol 2000; 165:3043-50.
21. Maxwell JR, Weinberg A, Prell RA, Vella AT. Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion. J Immunol 2000;164:107-12.
22. Lee SW, Park Y, Song A, Cheroutre H, Kwon BS, Croft M. Functional dichotomy between OX40 and 4-1BB in modulating effector CD8 T cell responses. J Immunol 2006;177:4464-72.
23. Ruby CE, Weinberg AD. The effect of aging on OX40 agonist-mediated cancer immunotherapy. Cancer Immunol Immunother 2009;58: 1941-7.
24. Petrausch U, Haley D, Miller W, Floyd K, Urba WJ, Walker E. Polychromatic flow cytometry: A rapid method for the reduction and analysis of complex multiparameter data. Cytometry A 2006;69: 1162-73.
25. Siebert JC, Wang L, Haley DP, Romer A, Zheng B, Munsil W, et al. Exhaustive expansion: A novel technique for analyzing complex data generated by higher-order polychromatic flow cytometry experiments. J Transl Med 2010;8:106.
26. Pitcher CJ, Hagen SI, Walker JM, Lum R, Mitchell BL, Maino VL, et al. Development and homeostasis of T cell memory in rhesus macaque. J Immunol 2002;168:29-43.
27. Chevalier N, Jarrossay D, Ho E, Avery DT, Ma CS, Yu D, et al. CXCR5 expressing human central memory CD4 T cells and their relevance for humoral immune responses. J Immunol 2011;186:5556-68.
28. Miller JD, van der Most RG, Akondy RS, Glidewell JT, Albott S, Masopust D, et al. Human effector andmemory CD8T cell responses to smallpox and yellow fever vaccines. Immunity 2008;28:710-22.
29. Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 2009;9:271-85.
30. Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001;19: 565-94.
31. Weinberg AD, Thalhofer C, Morris N, Walker JM, Seiss D,Wong S, et al. Anti-OX40 (CD134) administration to nonhuman primates: Immunostimulatory effects and toxicokinetic study. J Immunother 2006;29: 575-85.
32. Redmond WL, Weinberg AD. Targeting OX40 and OX40L for the treatment of autoimmunity and cancer. Crit Rev Immunol 2007;27: 415-36.
33. Kavanagh B, O'Brien S, Lee D, Hou Y, Weinberg V, Rini B, et al. CTLA4 blockade expands FoxP3 regulatory and activated effector CD4 T cells in a dose-dependent fashion. Blood 2008;112:1175-83.
34. Colombo MP, Piconese S. Regulatory-T-cell inhibition versus depletion: The right choice in cancer immunotherapy. Nat Rev Cancer 2007;7:880-7.
35. Kwek SS, Dao V, Roy R, Hou Y, Alajajian D, Simko JP, et al. Diversity of antigen-specific responses induced in vivo with ctla-4 blockade in prostate cancer patients. J Immunol 2012;189:3759-66.
36. Evans DE, Prell RA, Thalhofer CJ, Hurwitz AA, Weinberg AD. Engagement of OX40 enhances antigen-specific CD4() T cell mobilization/ memory development and humoral immunity: Comparison of alphaOX- 40 with alphaCTLA-4. J Immunol 2001;167:6804-11.
37. Morris NP, Peters C, Montler R, Hu HM, Curti BD, Urba WJ, et al. Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain. Mol Immunol 2007;44:3112-21.